• Cynosure earns FDA clearance for at-home wrinkle treatment device

    Cynosure (NASDAQ: CYNO) has received FDA clearance to market a home-use, over-the-counter device for treating facial wrinkles.
    July 19, 2012

    Cynosure (NASDAQ: CYNO; Westford, MA) has received FDA clearance to market a home-use, over-the-counter device for treating facial wrinkles. Developed in partnership with Unilever (NYSE: UL), the device treats both periorbital and perioral wrinkles, and is slated for commercial launch by Unilever in 2013.

    Worldwide sales of home-use aesthetic devices are expected to grow at a compound annual growth rate (CAGR) of 12.3% from $740.4 million in 2011 to more than $1.3 billion in 2016, says research firm Medical Insight. In North America alone, they estimate the home-use category is expected to grow at a CAGR of 12.1% from $451.6 million in 2011 to approximately $800 million by 2016.

    Cynosure signed a multi-year funded cooperative development agreement with Unilever in June 2009 to develop and commercialize light-based devices targeting the home-use personal care market.

    -----

    Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

    Laser Focus World has gone mobile: Get all of the mobile-friendly options here.

    Subscribe now to BioOptics World magazine; it's free!

    Sign up for Laser Focus World Newsletters
    Get the latest news and updates.

    Voice Your Opinion!

    To join the conversation, and become an exclusive member of Laser Focus World, create an account today!